menu
    • menu
    [{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Anastrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Juvise Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Juvise Pharmaceuticals \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Juvise Pharmaceuticals \/ Juvise Pharmaceuticals"},{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Bismuth Potassium Citrate","moa":"||Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juvise Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Juvise Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Juvise Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ponesimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Juvise Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Juvise Pharmaceuticals \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Juvise Pharmaceuticals \/ Juvise Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Juvise Pharmaceuticals

    Menu

    Juvise Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Juvise Pharmaceuticals

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Juvise Pharmaceuticals

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ponesimod

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Juvisé Pharmaceuticals Acquires Ponvory® Ex-US/Canada and Opens Capital To Bpifrance

                            Details : Juvise Pharmaceuticals will leverage its expertise to commercialize Ponvory (ponesimod), a first-line treatment option for active forms of relapsing multiple sclerosis outside of North America.

                            Product Name : Ponvory

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : Ponesimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Juvise Pharmaceuticals

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Juvise Pharmaceuticals

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            The French Specialty Pharmaceutical Company Juvisé Pharmaceuticals Has Successfully Completed a €400M Refin...

                            Details : Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.

                            Product Name : Pylera

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 07, 2022

                            Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Juvise Pharmaceuticals

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Juvise Pharmaceuticals

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anastrozole

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Juvise Pharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less than One Month

                            Details : Arimidex® (anastrozole) and Casodex® (bicalutamide) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.

                            Product Name : Arimidex

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 02, 2020

                            Lead Product(s) : Anastrozole

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth